title: Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
abstract: A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial. In this retrospective analysis, plasma samples from patients receiving capecitabine, oxaliplatin, and bevacizumab were analyzed to investigate biomarkers of clinical benefit. Forty-one protein biomarkers were tested in 38 patients at baseline and after two cycles of drug administration. Correlations among analytes were evaluated by Spearman analysis. Analyte levels at baseline and changes on-treatment were correlated with progression-free survival (PFS) and overall survival (OS) by univariate analysis. Multivariate analyses were determined using the Cox proportional hazard model. Time to event analyses were evaluated by Kaplan-Meier analysis and compared by log-rank test. Baseline levels of vWF and Ang-2 significantly correlated with PFS, while levels of VCAM-1, vWF, TSP-2, IL-8, MMP-2, and Ang-2 correlated with OS (P < 0.05). The fold change of IGF-1 levels from baseline to the end of cycle 2 was correlated with PFS, while fold changes of Ang-2, TSP-2, and TGF-β2 correlated with OS. A baseline signature of Ang-2, IGFBP-3, IL-6, and VCAM-1 identified a low-risk and high-risk group of patients (OS: 33.9 months vs. 18.1 months, respectively, P = 0.016). For treatment-related changes, a signature consisting of Ang-2, E-Cadherin, IL-6, MCP-1, OPN, and TGF-β1 was able to stratify patients into high- and low-risk groups (PFS: 7.7 months vs. 15.5 months, P = 0.004). Multiplex analysis of patient plasma in this trial identified several baseline- and treatment-related biomarkers associated with clinical outcome. These findings merit further exploration in larger, controlled clinical trials.
authors: Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
authors: Yingmiao
authors: Y
authors: Liu
authors: Mark D
authors: MD
authors: Starr
authors: Anuradha
authors: A
authors: Bulusu
authors: Herbert
authors: H
authors: Pang
authors: Nan Soon
authors: NS
authors: Wong
authors: Wanda
authors: W
authors: Honeycutt
authors: Anthony
authors: A
authors: Amara
authors: Herbert I
authors: HI
authors: Hurwitz
authors: Andrew B
authors: AB
authors: Nixon
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000097:blood*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000077150:Oxaliplatin; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil
keywords: Angiome; bevacizumab; biomarker; chemotherapy; colorectal cancer
references: Z Gastroenterol. 2011 Oct;49(10):1398-406
references: 21964893
references: Clin Colorectal Cancer. 2011 Sep;10(3):210-6
references: 21855046
references: Cancer Res. 2009 Oct 15;69(20):7905-10
references: 19826039
references: Ann Oncol. 2012 Jan;23(1):46-52
references: 21464158
references: Nat Rev Cancer. 2008 Aug;8(8):592-603
references: 18650835
references: Circ Res. 2008 Oct 24;103(9):916-8
references: 18818406
references: Br J Cancer. 2010 Oct 26;103(9):1407-14
references: 20924372
references: N Engl J Med. 2009 Apr 2;360(14):1408-17
references: 19339720
references: Biomed Pharmacother. 2000 Oct;54(8-9):431-6
references: 11100896
references: Nat Rev Mol Cell Biol. 2009 Mar;10(3):165-77
references: 19234476
references: EMBO J. 2001 Jun 1;20(11):2631-40
references: 11387198
references: Nat Rev Clin Oncol. 2012 Feb 14;9(5):297-303
references: 22330688
references: J Clin Oncol. 2008 Apr 20;26(12):2013-9
references: 18421054
references: J Clin Oncol. 2012 Feb 1;30(4):441-4
references: 22184396
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435
references: J Clin Oncol. 2007 Apr 20;25(12):1539-44
references: 17442997
references: Clin Cancer Res. 2013 Dec 15;19(24):6957-66
references: 24097873
references: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references: 19474385
references: Cytokine Growth Factor Rev. 2010 Feb;21(1):21-6
references: 20005148
references: Int J Colorectal Dis. 2002 Jan;17(1):42-5
references: 12018453
references: Cochrane Database Syst Rev. 2009 Jul 08;(3):CD005392
references: 19588372
references: Eur J Surg Oncol. 2007 Feb;33(1):7-15
references: 16962282
references: Br J Cancer. 2010 Jan 5;102(1):8-18
references: 20010945